In vitro activity of levonadifloxacin, the active drug of orally administered prodrug alalevonadifloxacin against bloodstream isolates of Burkholderia pseudomallei
CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH(2024)
Abstract
Background and objective: Eradication of Burkholderia pseudomallei infections requires prolonged antibiotic treatment indicating microbiological and pharmacokinetic limitations of current options. Methods and results: Levonadifloxacin, a novel benzoquinolizine-fluoroquinolone available intravenously and orally, showed greater activity than ciprofloxacin (MICs, 0.25 to 2 versus 0.25-8 mg/L) and comparable to doxycycline against 50 B. pseudomallei isolates. In time-kill assay, levonadifloxacin exerted rapid -3 log10 reduction while doxycycline was bacteriostatic. Conclusion: Levonadifloxacin merits further investigations as a potential treatment option for B. pseudomallei infections.
MoreTranslated text
Key words
Melioidosis,Burkholderia pseudomallei,Levonadifloxacin,Alalevonadifloxacin,Bactericidal
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined